BIOFLOW-VII: A Prospective Multicenter Study to Confirm the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions - VII

Grants and Contracts Details

StatusActive
Effective start/end date6/29/201/17/26

Funding

  • Biotronik Incorporated: $20,903.00